NEOTIGASON

This brand name is authorized in Australia, Brazil, Estonia, Spain, Finland, Hong Kong, Ireland, Israel, Italy, Lithuania, Malta, Netherlands, New Zealand, Poland, Singapore, Tunisia, Turkey, United Kingdom, South Africa

Active ingredients

The drug NEOTIGASON contains one active pharmaceutical ingredient (API):

1 Acitretin
UNII LCH760E9T7 - ACITRETIN

Acitretin, a synthetic aromatic derivative of retinoic acid, has a favourable therapeutic ratio, with a greater and more specific inhibitory effect on psoriasis and disorders of epithelial keratinisation. The usual therapeutic response to acitretin consists of desquamation (with or without erythema) followed by more normal re-epithelialisation. Acitretin is the main active metabolite of etretinate.

Read about Acitretin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
D05BB02 Acitretin D Dermatologicals → D05 Antipsoriatics → D05B Antipsoriatics for systemic use → D05BB Retinoids for treatment of psoriasis
Discover more medicines within D05BB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 2019G, 2020H
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 537519120008517, 537519120008617, 537519120008717, 537519120008817
Country: EE Ravimiamet Identifier(s): 1000731, 1834365, 1834376
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 60302, 60303
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 414953, 456335, 456343, 581493
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 26781, 26782
Country: HK Department of Health Drug Office Identifier(s): 39193, 39194
Country: IE Health Products Regulatory Authority Identifier(s): 19811, 28978, 55595, 61493
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 4540, 4541
Country: IT Agenzia del Farmaco Identifier(s): 027480019, 027480021
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1001361, 1088897, 1090627, 1091059, 1093400
Country: MT Medicines Authority Identifier(s): AA565/80401
Country: NL Z-Index G-Standaard, PRK Identifier(s): 29866, 29874
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 5224, 5225
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100046826, 100046832
Country: SG Health Sciences Authority Identifier(s): 08391P, 08392P
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 6993161, 6993162
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699638154777, 8699638154784
Country: ZA Health Products Regulatory Authority Identifier(s): W/13.4.2/73, W/13.4.2/74

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.